Seshadri P S
Lepr India. 1981 Jan;53(1):17-22.
Indication of an enhancing effect of Rifampicin on the urinary excretion of DDs has already been reported from this institution. Further observations on this aspect in 25 cases of lepromatous leprosy treated with a 15 day schedule of Rifampicin at a dose of 600 mg daily along with DDS are presented. The earlier findings that Rifampicin in the initial phase of administration enhance the urinary output of DDS are confirmed. An estimation of Rifampicin Creatinine levels in urine done concurrently also showed a quicker elimination of the drug in the earlier phase compared to later phases of the drug administration. As part of the study of drug interactions, the influence of Clofazimine administration on DDS metabolism was also studied. The findings indicate that Clofazimine does not exert any influence on DDs excretion by leprosy patients. The findings and their implications are discussed.
本机构已报告利福平对双乙酰二苯砜（DDS）尿排泄有增强作用。本文介绍了对25例瘤型麻风患者的进一步观察结果，这些患者接受了为期15天、每日剂量600毫克的利福平治疗，并同时服用DDS。早期关于利福平在给药初期可增加DDS尿量的发现得到了证实。同时进行的尿中利福平肌酐水平估计也显示，与给药后期相比，给药早期药物消除更快。作为药物相互作用研究的一部分，还研究了氯法齐明给药对DDS代谢的影响。研究结果表明，氯法齐明对麻风患者的DDS排泄没有任何影响。对这些发现及其意义进行了讨论。
